A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, David S.P. Tan, Tuan Zea Tan et al.|British Journal of Cancer|2025Cited by 2